Sosei : Announces Hart-Scott-Rodino Clearance for Global Collaboration between its Subsidiary Heptares Therapeutics and Allergan

96381b64-b835-4f12-8e23-708eb120a853.pdf Sosei Announces Hart-Scott-Rodino Clearance for Global Collaboration between its Subsidiary Heptares Therapeutics and Allergan Tokyo, Japan 26 May 2016: Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) today announces that the US Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR Act") in connection with the global collaboration agreement, executed on 7 April 2016, by Sosei's subsidiary Heptares Therapeutics Ltd with Allergan's subsidiary, Allergan Pharmaceuticals International Limited to develop and commercialise a broad portfolio of novel subtype-selective muscarinic receptor agonists for the treatment of major neurological disorders, including Alzheimer's disease.

With completion of the applicable waiting period under the HSR Act, the collaboration agreement with Allergan is effective as of 24 May 2016 under the terms previously announced on 7 April 2016, including the payment to Heptares of a $125 million upfront cash payment.

For further details of the agreement, please visit the Sosei website.

-Ends-

Enquiries: Sosei Group Corporation
Tokyo Office	London Office
Harumi BANSE, Investor Relations	Kathryn LYDON, Corporate Communications
+81-(0)3-5210-3399	+44-(0)20-7691-0983
hbanse@sosei.com	klydon@sosei.com

About Sosei

Sosei is a biopharmaceutical company originating from Japan but with global presence. Sosei's primary business model is based on identifying novel and/or differentiated product assets or technology platforms and, through supporting these in preclinical and clinical development and establishing commercial partnerships, advancing new medicines to patients worldwide.

For further information about Sosei, please visit www.sosei.com/en.

About Heptares Therapeutics

Heptares is a clinical-stage company creating transformative medicines targeting G protein-coupled receptors (GPCRs), a superfamily of 375 receptors linked to a wide range of human diseases. Heptares' proprietary StaR® technology and structure-based drug design (SBDD) capabilities enable us to engineer and develop drugs for highly

validated, yet historically undruggable or challenging GPCRs. Using this approach, we are building an exciting pipeline of new medicines (small molecules and biologics) with the potential to transform the treatment of Alzheimer's disease, schizophrenia, cancer immune-oncology, migraine, addiction, metabolic disease and other indications. We have partnerships for our novel candidates and technologies with leading pharmaceutical and biotechnology companies, including Allergan, AstraZeneca, Kymab, MedImmune, MorphoSys, Pfizer and Teva.

Heptares is a wholly owned subsidiary of Sosei Group Corporation. For more information, please visit www.heptares.com and www.sosei.com/en.

HEPTARES is a registered trademark in the EU, Switzerland, US and Japan; StaR® is a registered trademark in the EU and Japan.

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Sosei's actual results to differ materially from those expressed or implied by the forward- looking statements, including: adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.